A vs. COR: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at A and COR, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
COR’s market capitalization of 57.42 billion USD is significantly greater than A’s 34.48 billion USD, highlighting its more substantial market valuation.
A’s beta of 1.23 points to significantly higher volatility compared to COR (beta: 0.57), suggesting A has greater potential for both gains and losses relative to market movements.
| Symbol | A | COR |
|---|---|---|
| Company Name | Agilent Technologies, Inc. | Cencora, Inc. |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Diagnostics & Research | Medical - Distribution |
| CEO | Padraig McDonnell | Robert P. Mauch PharmD |
| Price | 121.38 USD | 296.23 USD |
| Market Cap | 34.48 billion USD | 57.42 billion USD |
| Beta | 1.23 | 0.57 |
| Exchange | NYSE | NYSE |
| IPO Date | November 18, 1999 | April 4, 1995 |
| ADR | No | No |
Historical Performance
This chart compares the performance of A and COR by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
A
19.46%
Medical - Diagnostics & Research Industry
- Max
- 57.35%
- Q3
- 18.17%
- Median
- 2.69%
- Q1
- -16.72%
- Min
- -48.78%
In the upper quartile for the Medical - Diagnostics & Research industry, A’s Return on Equity of 19.46% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
COR
240.99%
Medical - Distribution Industry
- Max
- 12.20%
- Q3
- 12.03%
- Median
- -50.14%
- Q1
- -62.68%
- Min
- -132.73%
COR’s Return on Equity of 240.99% is exceptionally high, placing it well beyond the typical range for the Medical - Distribution industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Return on Invested Capital
A
11.71%
Medical - Diagnostics & Research Industry
- Max
- 42.99%
- Q3
- 11.55%
- Median
- 3.02%
- Q1
- -11.49%
- Min
- -40.79%
In the upper quartile for the Medical - Diagnostics & Research industry, A’s Return on Invested Capital of 11.71% signifies a highly effective use of its capital to generate profits when compared to its peers.
COR
10.23%
Medical - Distribution Industry
- Max
- 26.59%
- Q3
- 11.51%
- Median
- 7.70%
- Q1
- -0.02%
- Min
- -5.86%
COR’s Return on Invested Capital of 10.23% is in line with the norm for the Medical - Distribution industry, reflecting a standard level of efficiency in generating profits from its capital base.
Net Profit Margin
A
17.59%
Medical - Diagnostics & Research Industry
- Max
- 22.76%
- Q3
- 15.19%
- Median
- 1.64%
- Q1
- -22.25%
- Min
- -78.24%
A Net Profit Margin of 17.59% places A in the upper quartile for the Medical - Diagnostics & Research industry, signifying strong profitability and more effective cost management than most of its peers.
COR
0.55%
Medical - Distribution Industry
- Max
- 3.21%
- Q3
- 2.07%
- Median
- 0.70%
- Q1
- -1.43%
- Min
- -6.29%
COR’s Net Profit Margin of 0.55% is aligned with the median group of its peers in the Medical - Distribution industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin
A
21.38%
Medical - Diagnostics & Research Industry
- Max
- 36.06%
- Q3
- 20.26%
- Median
- 6.15%
- Q1
- -21.89%
- Min
- -82.21%
An Operating Profit Margin of 21.38% places A in the upper quartile for the Medical - Diagnostics & Research industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
COR
0.83%
Medical - Distribution Industry
- Max
- 5.22%
- Q3
- 3.23%
- Median
- 1.07%
- Q1
- -0.39%
- Min
- -4.51%
COR’s Operating Profit Margin of 0.83% is around the midpoint for the Medical - Distribution industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | A | COR |
|---|---|---|
| Return on Equity (TTM) | 19.46% | 240.99% |
| Return on Assets (TTM) | 9.59% | 2.38% |
| Return on Invested Capital (TTM) | 11.71% | 10.23% |
| Net Profit Margin (TTM) | 17.59% | 0.55% |
| Operating Profit Margin (TTM) | 21.38% | 0.83% |
| Gross Profit Margin (TTM) | 53.79% | 3.29% |
Financial Strength
Current Ratio
A
2.09
Medical - Diagnostics & Research Industry
- Max
- 6.91
- Q3
- 4.11
- Median
- 2.46
- Q1
- 1.44
- Min
- 0.73
A’s Current Ratio of 2.09 aligns with the median group of the Medical - Diagnostics & Research industry, indicating that its short-term liquidity is in line with its sector peers.
COR
0.87
Medical - Distribution Industry
- Max
- 1.38
- Q3
- 1.26
- Median
- 1.13
- Q1
- 0.92
- Min
- 0.87
COR’s Current Ratio of 0.87 falls into the lower quartile for the Medical - Distribution industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio
A
0.57
Medical - Diagnostics & Research Industry
- Max
- 1.10
- Q3
- 0.82
- Median
- 0.39
- Q1
- 0.21
- Min
- 0.01
A’s Debt-to-Equity Ratio of 0.57 is typical for the Medical - Diagnostics & Research industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
COR
7.76
Medical - Distribution Industry
- Max
- 0.97
- Q3
- 0.97
- Median
- 0.65
- Q1
- 0.04
- Min
- 0.03
With a Debt-to-Equity Ratio of 7.76, COR operates with exceptionally high leverage compared to the Medical - Distribution industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
Interest Coverage Ratio
A
-472.33
Medical - Diagnostics & Research Industry
- Max
- 37.07
- Q3
- 5.62
- Median
- 1.76
- Q1
- -38.78
- Min
- -57.46
A has a negative Interest Coverage Ratio of -472.33. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
COR
9.41
Medical - Distribution Industry
- Max
- 25.45
- Q3
- 12.43
- Median
- 7.07
- Q1
- 1.82
- Min
- -1.21
COR’s Interest Coverage Ratio of 9.41 is positioned comfortably within the norm for the Medical - Distribution industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | A | COR |
|---|---|---|
| Current Ratio (TTM) | 2.09 | 0.87 |
| Quick Ratio (TTM) | 1.60 | 0.52 |
| Debt-to-Equity Ratio (TTM) | 0.57 | 7.76 |
| Debt-to-Asset Ratio (TTM) | 0.29 | 0.11 |
| Net Debt-to-EBITDA Ratio (TTM) | 1.43 | 1.60 |
| Interest Coverage Ratio (TTM) | -472.33 | 9.41 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for A and COR. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
A
0.81%
Medical - Diagnostics & Research Industry
- Max
- 2.76%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 0.81%, A offers a more attractive income stream than most of its peers in the Medical - Diagnostics & Research industry, signaling a strong commitment to shareholder returns.
COR
0.73%
Medical - Distribution Industry
- Max
- 1.21%
- Q3
- 0.56%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 0.73%, COR offers a more attractive income stream than most of its peers in the Medical - Distribution industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio
A
23.76%
Medical - Diagnostics & Research Industry
- Max
- 37.46%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
A’s Dividend Payout Ratio of 23.76% is in the upper quartile for the Medical - Diagnostics & Research industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
COR
25.13%
Medical - Distribution Industry
- Max
- 31.84%
- Q3
- 21.47%
- Median
- 5.24%
- Q1
- 0.00%
- Min
- 0.00%
COR’s Dividend Payout Ratio of 25.13% is in the upper quartile for the Medical - Distribution industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
Dividend at a Glance
| Symbol | A | COR |
|---|---|---|
| Dividend Yield (TTM) | 0.81% | 0.73% |
| Dividend Payout Ratio (TTM) | 23.76% | 25.13% |
Valuation
Price-to-Earnings Ratio
A
29.67
Medical - Diagnostics & Research Industry
- Max
- 48.28
- Q3
- 44.64
- Median
- 29.13
- Q1
- 22.34
- Min
- 15.59
A’s P/E Ratio of 29.67 is within the middle range for the Medical - Diagnostics & Research industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
COR
33.90
Medical - Distribution Industry
- Max
- 34.27
- Q3
- 27.58
- Median
- 25.75
- Q1
- 22.28
- Min
- 18.73
A P/E Ratio of 33.90 places COR in the upper quartile for the Medical - Distribution industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.
Forward P/E to Growth Ratio
A
3.80
Medical - Diagnostics & Research Industry
- Max
- 4.18
- Q3
- 3.64
- Median
- 2.40
- Q1
- 0.57
- Min
- 0.04
A Forward PEG Ratio of 3.80 places A in the upper quartile for the Medical - Diagnostics & Research industry. This suggests the stock is potentially expensive compared to its peers relative to its growth forecast, which may warrant caution.
COR
3.36
Medical - Distribution Industry
- Max
- 3.40
- Q3
- 2.79
- Median
- 2.36
- Q1
- 2.08
- Min
- 1.94
A Forward PEG Ratio of 3.36 places COR in the upper quartile for the Medical - Distribution industry. This suggests the stock is potentially expensive compared to its peers relative to its growth forecast, which may warrant caution.
Price-to-Sales Ratio
A
5.20
Medical - Diagnostics & Research Industry
- Max
- 12.53
- Q3
- 6.19
- Median
- 3.58
- Q1
- 1.95
- Min
- 0.58
A’s P/S Ratio of 5.20 aligns with the market consensus for the Medical - Diagnostics & Research industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
COR
0.19
Medical - Distribution Industry
- Max
- 1.08
- Q3
- 0.89
- Median
- 0.25
- Q1
- 0.18
- Min
- 0.06
COR’s P/S Ratio of 0.19 aligns with the market consensus for the Medical - Distribution industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio
A
5.64
Medical - Diagnostics & Research Industry
- Max
- 10.67
- Q3
- 5.74
- Median
- 2.95
- Q1
- 1.30
- Min
- 0.39
The P/B Ratio is often not a primary valuation metric for the Medical - Diagnostics & Research industry.
COR
56.68
Medical - Distribution Industry
- Max
- 8.13
- Q3
- 8.13
- Median
- 2.74
- Q1
- 2.19
- Min
- 1.20
At 56.68, COR’s P/B Ratio is at an extreme premium to the Medical - Distribution industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
Valuation at a Glance
| Symbol | A | COR |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 29.67 | 33.90 |
| Forward PEG Ratio (TTM) | 3.80 | 3.36 |
| Price-to-Sales Ratio (P/S, TTM) | 5.20 | 0.19 |
| Price-to-Book Ratio (P/B, TTM) | 5.64 | 56.68 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 24.63 | 16.06 |
| EV-to-EBITDA (TTM) | 25.95 | 17.22 |
| EV-to-Sales (TTM) | 5.51 | 0.20 |